Eloxx Pharmaceuticals Appoints Geno J. Germano to Board

• Eloxx Pharmaceuticals appointed Geno J. Germano to its board on October 19, 2026.
• The board expanded from five to six directors; Germano's term expires at the 2027 annual shareholder meeting.
• Germano served as president and CEO of Elucida Oncology from August 2018 to June 2024, following senior roles at Pfizer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-428116), on October 22, 2026, and is solely responsible for the information contained therein.